Avalo Therapeutics(US:AVTX)2020-08-13 22:04Pipeline Highlights - CERC-002 (anti-LIGHT mAb) is expected to deliver definitive topline POC data in Q4 2020 for COVID-19 ARDS [4] - CERC-007 (anti-IL-18 mAb) is expected to deliver initial data in multiple myeloma in 1Q 2021 and top line data in 2Q 2021, with initial data in Adult Onset Still's Disease (AOSD) by 2Q 2021 [4] - CERC-801 pivotal trial expected to start in 4Q 2020, with topline data expected in 4Q 2021 [4] - CERC-802 pivotal trial expected to start in 4Q 2020, with topline data expected in 3Q 2021 [4] - CERC-803 pivotal trial expected to start in 1H 2021, with topline data expected in 2H 2021 [4] - CERC-006 (dual mTOR inhibitor) initial data expected 2Q 2021 [4] CERC-007 (Anti-IL-18 mAb) in Multiple Myeloma and Adult Onset Still's Disease (AOSD) - Elevated IL-18 levels correlate with poor survival in multiple myeloma patients [15] - Patients with high IL-18 have significantly worse median survival (42 months vs >84 months, p value= 0.0026, HR = 1.84) [16] - Serum IL-18 correlates with disease severity in Adult Onset Still's Disease (AOSD) [19] CERC-006 (Dual mTOR Inhibitor) for Complex Lymphatic Malformations - Complex Lymphatic Malformations are orphan diseases with a combined US prevalence of 30,000 to 60,000, associated with high mortality rates of 20% to 50% over 3 to 7 years [27] CERC-002 (Anti-LIGHT mAb) for COVID-19 ARDS - Approximately 1,500 people in the United States die each day from COVID-19 [52] - In ventilated patients, LIGHT levels were higher in those patients that eventually died (93% mortality) than in those patients that recovered (20% mortality) [66] - In patients over 60, LIGHT levels were significantly higher in those that eventually died than in those patients that recovered (p=0.021), with an observed mortality rate of 82% compared to 32% in patients <60 years [69]